Last $5.20 USD
Change Today +0.21 / 4.21%
Volume 269.0K
ANAC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 5:20 PM 06/18/13 All times are local (Market data is delayed by at least 15 minutes).

anacor pharmaceuticals inc (ANAC) Snapshot

Open
$5.03
Previous Close
$4.99
Day High
$5.28
Day Low
$4.92
52 Week High
04/19/13 - $8.25
52 Week Low
02/27/13 - $3.00
Market Cap
210.6M
Average Volume 10 Days
338.3K
EPS TTM
$-1.71
Shares Outstanding
40.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANACOR PHARMACEUTICALS INC (ANAC)

anacor pharmaceuticals inc (ANAC) Latest News

More News

anacor pharmaceuticals inc (ANAC) Related Businessweek News

No Related Businessweek News Found

anacor pharmaceuticals inc (ANAC) Details

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company’s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed the Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Medicis Pharmaceutical Corporation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.

85 Employees
Last Reported Date: 03/18/13
Founded in 2000

anacor pharmaceuticals inc (ANAC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $504.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $335.0K
Senior Vice President of Program Management
Total Annual Compensation: $330.0K
Senior Vice President of Research
Total Annual Compensation: $330.0K
Senior Vice President of Drug Development
Total Annual Compensation: $270.0K
Compensation as of Fiscal Year 2012.

anacor pharmaceuticals inc (ANAC) Key Developments

Anacor Pharmaceuticals, Inc. Announces Loan Agreement with Hercules Technology Growth Capital, Inc and Hercules Technology Iii, L.P

Anacor Pharmaceuticals announced that it has entered into a loan agreement with Hercules Technology Growth Capital, Inc. for up to $45.0 million in new capital to be distributed in three tranches. Anacor borrowed the first tranche of $30.0 million upon the execution of the loan agreement on June 7, 2013 and used approximately $22.6 million to repay the remaining obligations under its loan agreement with Oxford Finance LLC and Horizon Technology Finance Corporation. Anacor expects to use the remainder of the funding for filing its New Drug Application (NDA) for tavaborole, conducting additional clinical studies of AN2728 and for general working capital. The second tranche of $10.0 million is available at Anacor's discretion through December 5, 2013, and the third tranche of $5.0 million is available upon confirmation of the U.S. Food and Drug Administration's (FDA) approval of the tavaborole NDA through the earlier of December 15, 2014 or 30 days after the FDA approval of tavaborole.

Anacor Pharmaceuticals Announces Successful Completion of Pre-NDA Communications with FDA for Tavaborole

Anacor Pharmaceuticals announced that it has successfully completed its pre-NDA (New Drug Application) communications with the Food and Drug Administration (FDA) related to tavaborole, its drug candidate for the topical treatment of onychomycosis. In its pre-NDA communications, Anacor achieved concurrence from the FDA on the content and format of the proposed NDA for tavaborole including required data related to safety, efficacy, manufacturing and packaging. Anacor remains on schedule to file the NDA in mid-2013.

Anacor Pharmaceuticals, Inc.(NasdaqGM:ANAC) added to NASDAQ Biotechnology Index

Anacor Pharmaceuticals, Inc. will be added to NASDAQ Biotechnology Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANAC:US $5.20 USD +0.21

ANAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANAC.
View Industry Companies
 

Industry Analysis

ANAC

Industry Average

Valuation ANAC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANACOR PHARMACEUTICALS INC, please visit www.anacor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.